Q-omics provides the consensus-scored TAGLN profile across patient tissues and cancer cell-line models. TAGLN expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, TAGLN is differentially expressed in 15, with the highest sampling consensus in KICH. Additionally, TAGLN protein abundance shows 24,413 significant protein co-abundance associations, with the highest sampling consensus in UCEC. Together, these results highlight KIRP, KICH, and UCEC as cancer lineages where TAGLN shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TAGLN — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TAGLN survival associations across molecular data types. TAGLN RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TAGLN RNA expression–survival associations across cancer types. High TAGLN expression shows unfavorable associations in KIRP, MESO, ACC, LGG and BLCA, but favorable associations in LIHC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for TAGLN RNA expression.
This table summarizes TAGLN tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 7. The strongest signals are observed in KICH for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for TAGLN. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TAGLN shows lower tumor expression in KICH, BLCA, KIRP, STAD and COAD and higher tumor expression in HNSC. The KICH box plot shows higher TAGLN RNA expression in normal versus tumor tissue (log2 FC = −3.341, t-test p < 0.001).
This table shows molecular features associated with TAGLN in patient tissues and cancer cell lines. In patient samples, TAGLN shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set. In cancer cell lines, TAGLN RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BONE and SKIN.
